Prostatype Genomics

Summary of the first half of 2024

1 January – 30 June 2024
• Net sales amounted to 115 TSEK (447)
• EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -18,437 TSEK (-19,575)
• Cash flow from current operations amounted to -23,211 TSEK (-19,200)
• Total cash flow for the period amounted to -935 TSEK (476)
• Earnings per share amounted to -0.02 SEK (-0.17)

CEO Fredrik Rickman comments:
“During the first half of 2024, a new promising chapter in the history of Prostatype Genomics began when we entered the US market with our genetic test Prostatype®, a market with annual sales of approximately 2 billion SEK and a potential that we estimate to be at least 6 billion SEK. At the same time, a multicentre study was completed in Spain with positive results, which means that many private healthcare providers and university hospitals in the country now want to start using Prostatype® as part of their clinical practice. We now have an exciting second half of the year ahead of us, with expected inclusion in Medicare’s reimbursement system (currently approx. 3,700 USD per test) in the United States in Q4 as the most important milestone.”